Petmed Express ( (PETS) ) has released its Q3 earnings. Here is a breakdown of the information Petmed Express presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
PetMed Express, Inc., also known as PetMeds, is a leading online retailer in the pet healthcare sector, offering a wide range of pharmaceuticals, prescription medications, and supplements across the United States. The company leverages telehealth and insurance partnerships to provide value and convenience to pet owners.
In its third-quarter fiscal 2025 earnings report, PetMed Express disclosed net sales of $53.0 million, achieving an adjusted EBITDA of $2.0 million, a notable increase from the previous year. The company highlighted its ongoing transformation efforts and the resulting operational efficiencies.
Key financial highlights include a gross margin rate of 28.1%, representing an improvement of 80 basis points year-over-year, and a reduction in general and administrative expenses by $2.6 million. Despite these improvements, the company reported a net loss of $0.7 million for the quarter. PetMed Express attributes its positive EBITDA growth to strategic investments and operational changes.
Looking ahead, PetMed Express remains committed to driving differentiation and sustainable growth, with a focus on enhancing shareholder value through continued operational excellence and financial discipline. The management’s strategy reflects a strong confidence in building a more efficient and resilient organization.
